Key clinical point: Combination sitravatinib and nivolumab can produce responses in patients with checkpoint inhibitor–refractory urothelial carcinoma.

Major finding: Of the 22 response-evaluable patients, 1 achieved a complete response, 5 had a partial response, 15 had stable disease, and 1 progressed.

Study details: Phase 2 trial of 33 patients previously exposed to platinum-based chemotherapy and checkpoint inhibitor therapy.

Disclosures: Mirati Therapeutics sponsored the trial. Dr. Msaouel disclosed relationships with Mirati, Bristol-Myers Squibb, Exelixis, Pfizer, and Takeda.